195 related articles for article (PubMed ID: 35124696)
21. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
Ates Ozdemir D; Usubutun A
Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
[TBL] [Abstract][Full Text] [Related]
22. Pan-cancer Analysis Reveals Cancer-dependent Expression of SOX17 and Associated Clinical Outcomes.
Xu LI; Bai Y; Cheng Y; Sheng X; Sun D
Cancer Genomics Proteomics; 2023; 20(5):433-447. PubMed ID: 37643784
[TBL] [Abstract][Full Text] [Related]
23. Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression.
Kuo IY; Wu CC; Chang JM; Huang YL; Lin CH; Yan JJ; Sheu BS; Lu PJ; Chang WL; Lai WW; Wang YC
Int J Cancer; 2014 Aug; 135(3):563-73. PubMed ID: 24407731
[TBL] [Abstract][Full Text] [Related]
24. Expression of WT1 and PAX8 in the epithelial tumours of Malaysian women with ovarian cancer.
Rhodes A; Vallikkannu N; Jayalakshmi P
Br J Biomed Sci; 2017 Apr; 74(2):65-70. PubMed ID: 28367736
[TBL] [Abstract][Full Text] [Related]
25. SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes.
Kuo IY; Huang YL; Lin CY; Lin CH; Chang WL; Lai WW; Wang YC
J Biomed Sci; 2019 Feb; 26(1):20. PubMed ID: 30777052
[TBL] [Abstract][Full Text] [Related]
26. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis.
Liliac L; Carcangiu ML; Canevari S; Căruntu ID; Ciobanu Apostol DG; Danciu M; Onofriescu M; Amălinei C
Rom J Morphol Embryol; 2013; 54(1):17-27. PubMed ID: 23529305
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of paired box genes 8 and 2 expression in epithelium tissues and the related tumors].
Song Y; Huang X; Shen GH; Liu XY; Zhang X
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):424-428. PubMed ID: 28635231
[No Abstract] [Full Text] [Related]
28. PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy.
Wang Y; Wang Y; Li J; Yuan Z; Yuan B; Zhang T; Cragun JM; Kong B; Zheng W
J Hematol Oncol; 2013 Aug; 6():60. PubMed ID: 23958394
[TBL] [Abstract][Full Text] [Related]
29. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study.
Tacha D; Zhou D; Cheng L
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):293-9. PubMed ID: 21285870
[TBL] [Abstract][Full Text] [Related]
30. Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.
Cheng L; Zhou S; Zhou S; Shi K; Cheng Y; Cai MC; Ye K; Lin L; Zhang Z; Jia C; Xiang H; Zang J; Zhang M; Yin X; Li Y; Di W; Zhuang G; Tan L
Cancer Res; 2022 Oct; 82(19):3588-3602. PubMed ID: 35857807
[TBL] [Abstract][Full Text] [Related]
31. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development.
Bowen NJ; Logani S; Dickerson EB; Kapa LB; Akhtar M; Benigno BB; McDonald JF
Gynecol Oncol; 2007 Feb; 104(2):331-7. PubMed ID: 17064757
[TBL] [Abstract][Full Text] [Related]
32. PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
Ghannam-Shahbari D; Jacob E; Kakun RR; Wasserman T; Korsensky L; Sternfeld O; Kagan J; Bublik DR; Aviel-Ronen S; Levanon K; Sabo E; Larisch S; Oren M; Hershkovitz D; Perets R
Oncogene; 2018 Apr; 37(17):2213-2224. PubMed ID: 29379162
[TBL] [Abstract][Full Text] [Related]
33. Screening the molecular targets of ovarian cancer based on bioinformatics analysis.
Du L; Qian X; Dai C; Wang L; Huang D; Wang S; Shen X
Tumori; 2015; 101(4):384-9. PubMed ID: 25953442
[TBL] [Abstract][Full Text] [Related]
34. PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation.
Gu X; Enane F; Tohme R; Schuerger C; Radivoyevitch T; Parker Y; Zuberi E; Przychodzen B; Jha BK; Lindner D; Rini B; Saunthararajah Y
Cell Rep; 2021 Sep; 36(12):109747. PubMed ID: 34551289
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic Signaling in Kidney Cancer Requires Renal Lineage Factor PAX8.
Cancer Discov; 2022 Aug; 12(8):1834. PubMed ID: 35713353
[TBL] [Abstract][Full Text] [Related]
36. Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma.
Mhawech-Fauceglia P; Wang D; Samrao D; Godoy H; Ough F; Liu S; Pejovic T; Lele S
Gynecol Oncol; 2012 Oct; 127(1):198-201. PubMed ID: 22705448
[TBL] [Abstract][Full Text] [Related]
37. Sox17 and β-catenin co-occupy Wnt-responsive enhancers to govern the endoderm gene regulatory network.
Mukherjee S; Chaturvedi P; Rankin SA; Fish MB; Wlizla M; Paraiso KD; MacDonald M; Chen X; Weirauch MT; Blitz IL; Cho KW; Zorn AM
Elife; 2020 Sep; 9():. PubMed ID: 32894225
[TBL] [Abstract][Full Text] [Related]
38. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
[TBL] [Abstract][Full Text] [Related]
39. PAX8 expression in ovarian surface epithelial cells.
Adler E; Mhawech-Fauceglia P; Gayther SA; Lawrenson K
Hum Pathol; 2015 Jul; 46(7):948-56. PubMed ID: 26079312
[TBL] [Abstract][Full Text] [Related]
40. The PAX8 cistrome in epithelial ovarian cancer.
Adler EK; Corona RI; Lee JM; Rodriguez-Malave N; Mhawech-Fauceglia P; Sowter H; Hazelett DJ; Lawrenson K; Gayther SA
Oncotarget; 2017 Dec; 8(65):108316-108332. PubMed ID: 29312534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
